Skip to search formSkip to main contentSkip to account menu

ICI 141292

Known as: ICI 141,292, ICI-141,292 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

epanolol

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Pharmacokinetics of Epanolol (ICI 141,292) in Healthy Young Volunteers and Comparative Data in Elderly Patients with Angina and Subjects with Renal or Hepatic Impairment
SummarySingle doses of epanolol (ICI 141,292) were administered to 12 healthy young male volunteers in a randomised crossover… 
2007
2007
ICI 141,292 (epanolol) —pharmacokinetics after single and repeated oral administration in the elderly with moderate renal impairment
SummaryThe pharmacokinetics of ICI 141,292 (epanolol) were studied over 3 days after a single oral 200 mg dose and then over 24 h… 
2004
2004
Assessment of the relative safety of the beta-blockers ICI 141,292 and atenolol in patients with bronchial asthma
SummaryICI 141,292 is a β-blocker with β1-selective partial agonist activity. To study its cardioselectivity in humans… 
2004
2004
Assessment of the relative safety of the beta-blockers ICI 141, 292 and atenolol in patients with bronchial asthma
1990
1990
Pharmacokinetic and pharmacodynamic studies in man with an antianginal agent 'Visacor'.
This randomized, double-blind, crossover study in 10 healthy male volunteers compared four single oral doses of ICI 141,292… 
1987
1987
Immediate haemodynamic effects of a novel partial agonist, beta 1-adrenoceptor blocking drug ICI 141,292 after intravenous administration to healthy young volunteers and patients with ischaemic heart…
ICI 141,292 is a new beta 1-adrenoceptor blocking drug. The beta 1-adrenoceptor antagonistic effect of ICI 141,292 was examined… 
1986
1986
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man.
The beta-adrenoceptor blocking properties and cardioselectivity of ICI 141, 292 were investigated in healthy male subjects. Seven… 
1984
1984
Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.
The objective of this placebo controlled double-blind multicentre (six centres) trial was to investigate the safety and efficacy… 
1984
1984
Absolute bioavailability study in the dog with visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity
SummaryThe cardioselective beta-adrenergic blocking drμg Visacor (ICI 141,292) was dosed to six beagle dogs in a randomized cross… 
1983
1983
Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292.
Six groups of four dogs were studied under pentobarbital anesthesia. Plasma levels of free fatty acids (FFA), glucose, insulin… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)